Sunshine Biopharma Inc. (SBFM)
Company Description
Sunshine Biopharma, Inc., a pharmaceutical and nutritional supplement company, focuses on the research and development of anticancer drugs.
The company is developing Adva-27a, a GEM-difluorinated C-glycoside derivative of podophyllotoxin to treat leukemia, lymphoma, testicular, lung, brain, prostate, bladder, colon, ovarian, liver, and other forms of cancers, as well as kills multidrug resistant cancer cells, including pancreatic cancer, breast cancer, small-cell lung cancer, and uterine sarcoma cells; and SBFM-PL4, an anti-coronavirus treatment compound.
It also offers Essential 9, a nutritional supplement tablet; and Calcium-Vitamin D supplement under the Essential Calcium-Vitamin D brand name, as well as develops and markets other science-based nutritional supplements.
The company has a license agreement with the University of Georgia to advance the development of its anti-coronavirus lead compound, SBFM-PL4.
Sunshine Biopharma, Inc. is headquartered in Pointe-Claire, Canada.

Country | CA |
IPO Date | Feb 15, 2022 |
Industry | Drug Manufacturers - Specialty & Generic |
Sector | Healthcare |
Employees | 52 |
CEO | Steve N. Slilaty |
Contact Details
Address: 6500 Trans-Canada Highway Pointe-Claire, QC CA | |
Website | https://www.sunshinebiopharma.com |
Stock Details
Ticker Symbol | SBFM |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001402328 |
CUSIP Number | 867781304 |
ISIN Number | US8677817004 |
Employer ID | 20-5566275 |
SIC Code | 8731 |
Key Executives
Name | Position |
---|---|
Dr. Steve N. Slilaty Ph.D. | Chairman, President & Chief Executive Officer |
Camille Sebaaly | Chief Financial Officer & Secretary |
Dr. Abderrazzak Merzouki | Chief Operating Officer & Director |
Malek Chamoun | Chief Development Officer |
Michel Roy | Chief Commercial Officer |
Robert G. Ferreira | President of Sunshine Bio Investments Inc |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Aug 14, 2025 | SCHEDULE 13G/A | [Amend] Filing |
Aug 12, 2025 | 10-Q | Quarterly Report |
Aug 12, 2025 | 424B3 | Filing |
Aug 12, 2025 | RW | Filing |
Aug 05, 2025 | S-1 | Filing |
Jul 25, 2025 | POS AM | Filing |
Jun 12, 2025 | SCHEDULE 13G/A | [Amend] Filing |
May 23, 2025 | SCHEDULE 13G | Filing |
May 19, 2025 | 8-K | Current Report |
May 15, 2025 | 10-Q | Quarterly Report |